Patents by Inventor Guosen Ye
Guosen Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250136722Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.Type: ApplicationFiled: August 12, 2022Publication date: May 1, 2025Inventors: Peiling CHEN, Michael Gerard DARCY, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Andrew Peter MARCUS, Joseph Paul MARINO, Jeffrey Alan OPLINGER, James P. PHELAN, Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG, Jae U. JEONG
-
Publication number: 20250057958Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.Type: ApplicationFiled: August 13, 2024Publication date: February 20, 2025Inventors: Peiling Chen, Michael Gerard Darcy, Jason W. Dodson, Beth Anne Knapp-Reed, Joseph Paul Marino, JR., Jeffrey Alan Oplinger, Matthew Robert Sender, Brandon James Turunen, Guosen Ye, Cunyu Zhang
-
Publication number: 20240325392Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.Type: ApplicationFiled: February 9, 2024Publication date: October 3, 2024Inventors: Peiling CHEN, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Joseph Paul MARINO, JR., Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG
-
Patent number: 11976057Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.Type: GrantFiled: October 4, 2021Date of Patent: May 7, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III
-
Patent number: 11970480Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: GrantFiled: May 17, 2022Date of Patent: April 30, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
-
Publication number: 20230071675Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: ApplicationFiled: May 17, 2022Publication date: March 9, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
-
Publication number: 20220112174Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.Type: ApplicationFiled: October 4, 2021Publication date: April 14, 2022Inventors: Edward BRNARDIC, Michael BURY, Rodolfo CADILLA, Jon COLLINS, Yu GUO, Anthony HANDLON, Huijie LI, Yue LI, Daniel PAONE, Christie SCHULTE, Barry SHEARER, Guosen YE, Maben YING, Huichang ZHANG
-
Patent number: 11229623Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: February 21, 2020Date of Patent: January 25, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITEDInventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
-
Publication number: 20210238172Abstract: The invention relates to combinations comprising a compound of the formula: or a salt thereof; and one or more additional pharmaceutically agents active against HIV, and methods of using the same.Type: ApplicationFiled: October 4, 2018Publication date: August 5, 2021Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Adam Kenneth CHARNLEY, Michael Gerard DARCY, Jason W. DODSON, Xiaoyang DONG, David FAVRE, Terry Vincent HUGHES, Jianxing KANG, Lara Kathryn LEISTER, Yuehu LI, Yiqian LIAN, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
-
Patent number: 10968209Abstract: The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound.Type: GrantFiled: May 18, 2017Date of Patent: April 6, 2021Inventors: Patrick Stoy, Carl A. Brooks, Guosen Ye
-
Publication number: 20200308160Abstract: The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound.Type: ApplicationFiled: May 18, 2017Publication date: October 1, 2020Inventors: Patrick STOY, Carl A. BROOKS, Guosen YE
-
Publication number: 20200261411Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: February 21, 2020Publication date: August 20, 2020Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Linda S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jaclyn R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
-
Publication number: 20200095217Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: ApplicationFiled: October 17, 2019Publication date: March 26, 2020Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
-
Patent number: 10588891Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: September 20, 2017Date of Patent: March 17, 2020Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
-
Patent number: 10450288Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: GrantFiled: January 9, 2015Date of Patent: October 22, 2019Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
-
Publication number: 20190216774Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: September 20, 2017Publication date: July 18, 2019Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Lisa S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jacyln R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
-
Publication number: 20160340328Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: ApplicationFiled: January 9, 2015Publication date: November 24, 2016Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
-
Patent number: 9487507Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: June 15, 2012Date of Patent: November 8, 2016Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
-
Patent number: 9187464Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.Type: GrantFiled: June 15, 2012Date of Patent: November 17, 2015Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye
-
Publication number: 20140121206Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.Type: ApplicationFiled: June 15, 2012Publication date: May 1, 2014Applicant: GlaxoSmithKliine, LLCInventors: Carl Brooks, Mui Cheung, Hilary Schenck Eidam, Krista B. Goodman, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Jaclyn R. Patterson, Patrick Stoy, Guosen Ye